Melanoma and MAPK Pathways
Melanoma and MAPK Pathways is a research topic within Molecular Biology. Science Explorer counts 20k research works in it since 1950. 19.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the mammalian MAP kinase signaling pathways, particularly their role in cancer, with a specific emphasis on melanoma. It covers the genetic mutations, targeted therapies, resistance mechanisms, and the impact of MAP kinase pathways on cell proliferation and immune response.
- MAP Kinase
- BRAF gene
- Melanoma
- Signal Transduction
- ERK pathway
- Cancer Therapy
- MEK Inhibition
- Cell Proliferation
- Oncogenic Mutations
- Immune Response
- Research works
- 20k fractional, since 1950
- In the world top 10%
- 3.7k per year above
- Top-10% rate
- 19.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +4% the tick is no change
Which countries lead Melanoma and MAPK Pathways research?
By volume, the United States and China publish the most (1k and 558 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1k works
- 2 China 558 works
- 3 Germany 168 works
- 4 Italy 167 works
- 5 Japan 146 works
- 6 France 128 works
- 7 India 115 works
- 8 United Kingdom 113 works
- 9 Australia 103 works
- 10 Spain 96 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Melanoma and MAPK Pathways research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Melanoma and MAPK Pathways research, followed by Moffitt Cancer Center and University of North Carolina at Chapel Hill.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 33 works
- 2 Moffitt Cancer CenterUnited States 17 works
- 3 University of North Carolina at Chapel HillUnited States 17 works
- 4 Memorial Sloan Kettering Cancer CenterUnited States 17 works
- 5 Harvard UniversityUnited States 16 works
- 6 Massachusetts General HospitalUnited States 15 works
- 7 Melanoma Institute AustraliaAustralia 11 works
- 8 Istituti di Ricovero e Cura a Carattere ScientificoItaly 11 works
- 9 The University of SydneyAustralia 11 works
- 10 Yale UniversityUnited States 11 works
Who are the leading researchers in Melanoma and MAPK Pathways?
The most-cited researchers publishing on Melanoma and MAPK Pathways include Dirk Schadendorf, Michael Karin and Gordon B. Mills.
- 1 Dirk Schadendorf Germany 4.4k citations
- 2 Michael Karin United States 4k citations
- 3 Gordon B. Mills United States 3.7k citations
- 4 Larry Rubinstein United States 3.6k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Melanoma and MAPK Pathways research done?
The largest centres of Melanoma and MAPK Pathways research in 2022–2025 are New York (United States), Beijing (China), Shanghai (China) and Houston (United States). Among places with at least 20 works in it, it is an unusually large share of all research in Tampa, Heidelberg and Houston.
Largest cities, 2022–2025
Where it is the local speciality
- TampaUS · 23.2 works10×
- HeidelbergDE · 21.7 works6.4×
- HoustonUS · 46.8 works5.7×
- San FranciscoUS · 21.8 works5.1×
Location quotient: how much more of its research is in Melanoma and MAPK Pathways than the world average.
Where is the best place to study Melanoma and MAPK Pathways?
Among universities, judged by research, Harvard University, Icahn School of Medicine at Mount Sinai and Sichuan University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Harvard UniversityUnited States | 47.0 | 25.2% | 4.0× | 16 | -2.2% |
| 2 | Icahn School of Medicine at Mount SinaiUnited States | 43.8 | 18.3% | 5.7× | 9 | +315.7% |
| 3 | Sichuan UniversityChina | 43.5 | 29.1% | 1.9× | 11 | +121.4% |
| 4 | The University of SydneyAustralia | 41.5 | 26.6% | 3.5× | 11 | -4.5% |
| 5 | University of TübingenGermany | 39.8 | 19.1% | 7.7× | 10 | -9.2% |
| 6 | Cornell UniversityUnited States | 34.5 | 25.1% | 2.7× | 9 | +36.4% |
| 7 | Johns Hopkins UniversityUnited States | 33.5 | 25.3% | 2.6× | 9 | +15.8% |
| 8 | Peking UniversityChina | 28.8 | 20.8% | 1.9× | 10 | +65.0% |
| 9 | Yale UniversityUnited States | 25.7 | 18.1% | 3.4× | 11 | -8.7% |
| 10 | University of North Carolina at Chapel HillUnited States | 20.5 | 10.3% | 3.1× | 17 | +48.8% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Melanoma and MAPK Pathways research growing?
Output in 2018–2022 was 4% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Melanoma and MAPK Pathways.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.